Valuation : Sernova Biotherapeutics Inc

Market Cap 41.54M 29.97M 25.72M 24.08M 22.05M 2.86B 41.66M 285M 111M 1.44B 113M 110M 4.77B P/E 2026 *
-3.67x
P/E 2027 * -2.75x
Enterprise Value 41.54M 29.97M 25.72M 24.08M 22.05M 2.86B 41.66M 285M 111M 1.44B 113M 110M 4.77B EV / Sales 2026 *
-
EV / Sales 2027 * 8.31x
Free-Float
86.84%
Yield 2026 *
-
Yield 2027 * -
1 month-8.33%
3 months-21.43%
6 months-21.43%
Current year-15.38%
1 week 0.1
Extreme 0.105
0.12
1 month 0.1
Extreme 0.1
0.12
Current year 0.1
Extreme 0.1
0.2
1 year 0.1
Extreme 0.1
0.2
3 years 0.1
Extreme 0.1
0.91
5 years 0.1
Extreme 0.1
2.22
10 years 0.1
Extreme 0.095
2.87
Manager TitleAgeSince
Chief Executive Officer 58 2024-08-11
Director of Finance/CFO 60 2024-10-10
Investor Relations Contact - 2024-10-10
Director TitleAgeSince
Director/Board Member 60 2012-04-18
Director/Board Member - 2023-04-23
Director/Board Member - 2024-08-31
Date Insider Type Main position Quantity % Market Cap.
7/3/26 SellCompany -115,000 0.0305%
5/22/26 Option

Chairman

228,912 0.0658%
5/22/26 Option

Director

260,000 0.0748%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-40.54%-85.33% 29.97M
+1.59%-0.52%-15.90%+17.76% 124B
-1.14%-0.89%-23.02%-1.21% 12.26B
-0.68%-2.11%+87.43%+144.50% 10.72B
+0.28%-3.12%-50.49%-68.68% 4.21B
-0.42%+1.76%-16.33%+56.71% 2.73B
+1.23%-0.87%-32.41%-71.72% 1.76B
-0.45%-3.30%-19.33%-13.90% 1.63B
-5.12%-9.19%-40.28%-40.63% 1.6B
Average -0.51%-0.51%-16.76%-6.94% 17.61B
Weighted average by Cap. +1.07%-1.41%-10.85%+21.31%

Financials

2026 *2027 *
Net sales - 5M 3.61M 3.1M 2.9M 2.65M 344M 5.01M 34.32M 13.42M 174M 13.54M 13.25M 575M
Net income -12.83M -9.25M -7.94M -7.44M -6.81M -884M -12.86M -88.05M -34.42M -445M -34.74M -33.99M -1.47B -19.77M -14.26M -12.24M -11.46M -10.5M -1.36B -19.83M -136M -53.06M -687M -53.55M -52.39M -2.27B
Net Debt - -
Logo Sernova Biotherapeutics Inc
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
8
Date Price Change Volume
26-08-27 CA$0.1100 0.00% 51,456
26-08-26 CA$0.1100 0.00% 4,000
26-08-25 CA$0.1100 0.00% 68,110
26-08-24 CA$0.1100 0.00% 40,202
26-08-21 CA$0.1100 0.00% 121,565
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1100CAD
Average target price
0.4500CAD
Spread / Average Target
+309.09%

Quarterly revenue - Rate of surprise